Stock LVTX LAVA THERAPEUTICS N.V.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages LAVA Therapeutics N.V.

Equities

LVTX

NL0015000AG6

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-23 pm EDT 		5-day change 1st Jan Change
2.98 USD +4.56% Intraday chart for LAVA Therapeutics N.V. +3.11% +88.61%
Mar. 20 LAVA Therapeutics N.V. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Mar. 20 LAVA Therapeutics N.V. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
LAVA Therapeutics N.V. Reports Earnings Results for the Full Year Ended December 31, 2023
LAVA Therapeutics N.V. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
LAVA Therapeutics N.V. Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052
Sector Update: Health Care Stocks Softer Late Afternoon
Sector Update: Health Care Stocks Slipping Thursday Afternoon
Sector Update: Health Care
Lava Therapeutics to Study Gammabody Combined With Merck's Keytruda to Treat Metastatic Prostate Cancer
Upbeat US Economic Growth Data Lift Sentiment, Driving Premarket Gains for US Equity Futures
Top Premarket Gainers
LAVA Therapeutics Announces Collaboration with Merck & Co., Inc. to Evaluate LAVA-1207 in Combination with KEYTRUDA
LAVA Therapeutics N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
LAVA Therapeutics N.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Lava Therapeutics to Halt LAVA-051 Clinical Trial, Focus on Potential Prostate Cancer Treatment LAVA-1207
LAVA Therapeutics N.V. Provides Updates on Clinical Programs and Extends the Cash Runway
LAVA Therapeutics N.V. Reports Earnings Results for the First Quarter Ended March 31, 2023
Sector Update: Health Care Stocks Rising Late Friday
Sector Update: Health Care
Top Midday Gainers
Top Premarket Gainers
LAVA Therapeutics Shares Rise Premarket Following Selection by Janssen Biotech to Support Development of Cancer Treatment
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LVTX Stock
  4. News LAVA Therapeutics N.V.
  5. Other languages